MedTrace Logo

Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria

NCT01115439 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2012-07-12

No results posted yet for this study

Summary

In Afghanistan, studies over the past 15 years have shown a high degree of Plasmodium falciparum resistance to chloroquine (80%) and more recently an increasing degree of resistance to sulfadoxine-pyrimethamine monotherapy (12%). In 2003 the high failure rate of chloroquine against falciparum malaria led the national malaria treatment programme to switch its recommended first line drug treatment for uncomplicated Plasmodium falciparum malaria to artemisinin-based combination therapy (ACT) in the form of Artesunate/Sulfadoxine-Pyrimethamine (AS+SP). Second line drug treatment is oral quinine (7 days). The aim of this study is to conduct ongoing monitoring of the efficacy of the new combination against P. falciparum in a group of sentinel sites in Afghanistan.

Conditions

  • Falciparum Malaria

Interventions

DRUG

artesunate plus sulfadoxine-pyrimethamine (AS+SP)

artesunate plus sulfadoxine-pyrimethamine (AS+SP)

Sponsors & Collaborators

  • National Malaria and Leishmaniasis Control Program, Afghanistan

    collaborator OTHER_GOV

  • World Health Organization

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Ghulam Rahim Awab, MD · Mahidol Oxford Tropical Medicine Research Unit

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-04-30
Completion
2011-07-31

Countries

  • Afghanistan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01115439 on ClinicalTrials.gov